4649 related articles for article (PubMed ID: 36274602)
21. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
[TBL] [Abstract][Full Text] [Related]
22. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
[TBL] [Abstract][Full Text] [Related]
23. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007.
Fiore AE; Shay DK; Haber P; Iskander JK; Uyeki TM; Mootrey G; Bresee JS; Cox NJ;
MMWR Recomm Rep; 2007 Jul; 56(RR-6):1-54. PubMed ID: 17625497
[TBL] [Abstract][Full Text] [Related]
24. Seasonal influenza vaccines.
Fiore AE; Bridges CB; Cox NJ
Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
[TBL] [Abstract][Full Text] [Related]
25. Recommendations for Prevention and Control of Influenza in Children, 2018-2019.
COMMITTEE ON INFECTIOUS DISEASES
Pediatrics; 2018 Oct; 142(4):. PubMed ID: 30177511
[TBL] [Abstract][Full Text] [Related]
26. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
29. Vaccines for preventing influenza in healthy children.
Jefferson T; Rivetti A; Di Pietrantonj C; Demicheli V
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD004879. PubMed ID: 29388195
[TBL] [Abstract][Full Text] [Related]
30. [Consideration on implementation of co-administration of Seasonal Influenza and COVID-19 vaccines during pandemic in China].
Zhang T; Bai XF; Wang W; Liu XX; Zhang XX; Wang DY; Zhang SB; Chen ZP; He HQ; Huang ZY; Xu AQ; Peng ZB; Feng LZ; Yu WZ; Feng Z
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Feb; 56(2):103-107. PubMed ID: 34954956
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial.
Chen H; Huang Z; Chang S; Hu M; Lu Q; Zhang Y; Wang H; Xiao Y; Wang H; Ge Y; Zou Y; Cui F; Han S; Zhang M; Wang S; Zhu X; Zhang B; Li Z; Ren J; Chen X; Ma R; Zhang L; Guo X; Luo L; Sun X; Yang X
Vaccine; 2022 Aug; 40(36):5322-5332. PubMed ID: 35931636
[TBL] [Abstract][Full Text] [Related]
32. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
Fiore AE; Shay DK; Broder K; Iskander JK; Uyeki TM; Mootrey G; Bresee JS; Cox NJ;
MMWR Recomm Rep; 2009 Jul; 58(RR-8):1-52. PubMed ID: 19644442
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B
Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430
[TBL] [Abstract][Full Text] [Related]
35. Who should be prioritized for COVID-19 vaccination in China? A descriptive study.
Yang J; Zheng W; Shi H; Yan X; Dong K; You Q; Zhong G; Gong H; Chen Z; Jit M; Viboud C; Ajelli M; Yu H
BMC Med; 2021 Feb; 19(1):45. PubMed ID: 33563270
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
37. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic.
Ropero-Álvarez AM; El Omeiri N; Kurtis HJ; Danovaro-Holliday MC; Ruiz-Matus C
Hum Vaccin Immunother; 2016 Aug; 12(8):2206-2214. PubMed ID: 27196006
[TBL] [Abstract][Full Text] [Related]
38. Acceptability, cost-effectiveness, and capacity of a facility-based seasonal influenza vaccination among high-risk groups: a study protocol in selected tertiary care hospitals of Bangladesh.
Hassan MZ; Biswas MAAJ; Rahman M; Shoshi HR; Pyash AS; Islam MA; Haque MA; Parvin SR; Hossen MT; Hussain M; Rahman M; Shirin T; Chowdhury F
BMC Public Health; 2024 Jan; 24(1):242. PubMed ID: 38245668
[TBL] [Abstract][Full Text] [Related]
39. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
40. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
Claeys C; Drame M; García-Sicilia J; Zaman K; Carmona A; Tran PM; Miranda M; Martinón-Torres F; Thollot F; Horn M; Schwarz TF; Behre U; Merino JM; Sadowska-Krawczenko I; Szymański H; Schu P; Neumeier E; Li P; Jain VK; Innis BL
BMC Infect Dis; 2018 Apr; 18(1):186. PubMed ID: 29669531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
